The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients
Open accessAbstract
BACKGROUND: Patients with acute medical illnesses are at prolonged risk for venous thrombosis. However, the appropriate duration of thromboprophylaxis remains unknown. METHODS: Patients who were hospitalized for acute medical illnesses were randomly assigned to receive subcutaneous enoxaparin (at a dose of 40 mg once daily) for 10±4 days plus oral betrixaban placebo for 35 to 42 days or subcutaneous enoxaparin placebo for 10±4 days plus oral betrixaban (at a dose of 80 mg once daily) for 35 to 42 days. We performed sequential analyses in three prespecified, progressively inclusive cohorts: patients with an elevated d-dimer level (cohort 1), patients with an elevated d-dimer level or an age of at least 75 years (cohort 2), and all the enrolled patients (overall population cohort). The statistical analysis plan specified that if the between-group difference in any analysis in this sequence was not significant, the other analyses would be considered exploratory. The primary efficacy outcome was a composite of asymptomatic proximal deep-vein thrombosis and symptomatic venous thromboembolism. The principal safety outcome was major bleeding. RESULTS: A total of 7513 patients underwent randomization. In cohort 1, the primary efficacy outcome occurred in 6.9% of patients receiving betrixaban and 8.5% receiving enoxaparin (relative risk in the betrixaban group, 0.81; 95% confidence interval [CI], 0.65 to 1.00; P=0.054). The rates were 5.6% and 7.1%, respectively (relative risk, 0.80; 95% CI, 0.66 to 0.98; P=0.03) in cohort 2 and 5.3% and 7.0% (relative risk, 0.76; 95% CI, 0.63 to 0.92; P=0.006) in the overall population. (The last two analyses were considered to be exploratory owing to the result in cohort 1.) In the overall population, major bleeding occurred in 0.7% of the betrixaban group and 0.6% of the enoxaparin group (relative risk, 1.19; 95% CI, 0.67 to 2.12; P=0.55). CONCLUSIONS: Among acutely ill medical patients with an elevated d-dimer level, there was no significant difference between extended-duration betrixaban and a standard regimen of enoxaparin in the prespecified primary efficacy outcome. However, prespecified exploratory analyses provided evidence suggesting a benefit for betrixaban in the two larger cohorts. (Funded by Portola Pharmaceuticals; APEX ClinicalTrials.gov number, NCT01583218.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
Kahn (2012) · doi:10.1378/chest.11-2296 · Cited by 2,693
Samama, M. M., Cohen, A. T., Darmon, J.-Y., Desjardins, L., Eldor, A., Janbon, C., Leizorovicz, A., Nguyen, H., Olsson, C.-G., Turpie, A. G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909093411103 · Cited by 1,584
Self-citationAgnelli, G., Anderson, F., Arcelus, J., Bergqvist, D., Brecht, J., Greer, I., Heit, J., Hutchinson, J., Kakkar, A., Mottier, D., et al. (2007) · Thrombosis and Haemostasis · doi:10.1160/th07-03-0212 · Cited by 1,566
Self-citationThrombosis: A Major Contributor to Global Disease Burden
Raskob, G. E., Angchaisuksiri, P., Blanco, A. N., Buller, H., Gallus, A., Hunt, B. J., Hylek, E. M., Kakkar, A., Konstantinides, S. V., McCumber, M., et al. (2014) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.114.304488 · Cited by 1,158
Heit, J. A., O'Fallon, W. M., Petterson, T. M., Lohse, C. M., Silverstein, M. D., Mohr, D. N., & Melton, L. J. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.11.1245 · Cited by 1,104
Leizorovicz, A., Cohen, A. T., Turpie, A. G. G., Olsson, C.-G., Vaitkus, P. T., & Goldhaber, S. Z. (2004) · Circulation · doi:10.1161/01.cir.0000138928.83266.24 · Cited by 955
Self-citationCohen, A. T., Davidson, B. L., Gallus, A. S., Lassen, M. R., Prins, M. H., Tomkowski, W., Turpie, A. G. G., Egberts, J. F. M., & Lensing, A. W. A. (2006) · BMJ · doi:10.1136/bmj.38733.466748.7c · Cited by 857
Self-citationSamama, M.-M. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.22.3415 · Cited by 695
Eyer, M. M., Amama, M. I. S., Lexander, A., Ohen, T. H. C., Ean, J., Armon, V. D., Esjardins, L. O. D., Ldor, A. M. E., Anbon, C. H. J., Eizorovicz, A. L. L., et al. (1999) · Cited by 623
Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients
Cohen, A. T., Spiro, T. E., Büller, H. R., Haskell, L., Hu, D., Hull, R., Mebazaa, A., Merli, G., Schellong, S., Spyropoulos, A. C., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1111096 · Cited by 607
Self-citationApixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients
Goldhaber, S. Z., Leizorovicz, A., Kakkar, A. K., Haas, S. K., Merli, G., Knabb, R. M., & Weitz, J. I. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1110899 · Cited by 547
Self-citationDentali, F., Douketis, J. D., Gianni, M., Lim, W., & Crowther, M. A. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-4-200702200-00007 · Cited by 544
Alikhan, R., Cohen, A. T., Combe, S., Samama, M. M., Desjardins, L., Eldor, A., Janbon, C., Leizorovicz, A., Olsson, C.-G., & Turpie, A. G. G. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.9.963 · Cited by 481
Self-citationHull, R. D., Schellong, S. M., Tapson, V. F., Monreal, M., Samama, M.-M., Nicol, P., Vicaut, E., Turpie, A. G. G., Yusen, R. D., & study*, F. T. E. (. P. F. V. T. I. A. I. M. P. W. P. I. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-1-201007060-00004 · Cited by 384
Self-citationIdraparinux versus Standard Therapy for Venous Thromboembolic Disease
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa064247 · Cited by 335
Nadroparin in the Prevention of Deep Vein Thrombosis in Acute Decompensated COPD
FRAISSE, F., HOLZAPFEL, L., COULAND, J.-M., SIMONNEAU, G., BEDOCK, B., FEISSEL, M., HERBECQ, P., PORDES, R., POUSSEL, J.-F., ROUX, L., et al. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.4.9807025 · Cited by 300
Estimated annual numbers of US acute‐care hospital patients at risk for venous thromboembolism
Anderson, F. A., Zayaruzny, M., Heit, J. A., Fidan, D., & Cohen, A. T. (2007) · American Journal of Hematology · doi:10.1002/ajh.20983 · Cited by 288
Self-citationAssessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients
Alikhan, R., Arcelus, J. I., Bergmann, J.-F., Haas, S., Merli, G. J., Spyropoulos, A. C., Tapson, V. F., Turpie, A. G. G., & Cohen, A. T. (2005) · Thrombosis and Haemostasis · doi:10.1160/th05-06-0385 · Cited by 249
Self-citationDuration of venous thromboembolism risk across a continuum in medically ill hospitalized patients
Amin, A., Varker, H., Princic, N., Lin, J., Thompson, S., & Johnston, S. S. (2011) · Journal of Hospital Medicine · doi:10.1002/jhm.1002 · Cited by 152
Analysis of a binary composite endpoint with missing data in components
Quan, H., Zhang, D., Zhang, J., & Devlamynck, L. (2007) · Statistics in Medicine · doi:10.1002/sim.2893 · Cited by 14
Cited by
Bikdeli, B., Madhavan, M. V., Jimenez, D., Chuich, T., Dreyfus, I., Driggin, E., Nigoghossian, C. D., Ageno, W., Madjid, M., Guo, Y., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.04.031 · Cited by 2,885
Self-citationLyman, G. H., Carrier, M., Ay, C., Di Nisio, M., Hicks, L. K., Khorana, A. A., Leavitt, A. D., Lee, A. Y. Y., Macbeth, F., Morgan, R. L., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003442 · Cited by 893
Schünemann, H. J., Cushman, M., Burnett, A. E., Kahn, S. R., Beyer-Westendorf, J., Spencer, F. A., Rezende, S. M., Zakai, N. A., Bauer, K. A., Dentali, F., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018022954 · Cited by 819
Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges
Chen, A., Stecker, E., & A. Warden, B. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.017559 · Cited by 666
Weitz, J. I., Fredenburgh, J. C., & Eikelboom, J. W. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.09.024 · Cited by 582
Metadata
- Authors
- Cohen, A. T., Harrington, R. A., Goldhaber, S. Z., Hull, R. D., Wiens, B. L., Gold, A., Hernandez, A. F., & Gibson, C. M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-08-11
- Volume
- 375
- Issue
- 6
- Pages
- 534-544
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2407139997
- Cited by
- 441
- References
- 21
- FWCI
- 53.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.